Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma.

Sprinzl MF, Kirstein MM, Koch S, Seib ML, Weinmann-Menke J, Lang H, Düber C, Toenges G, Zöller D, Marquardt JU, Wörns MA, Galle PR, Vogel A, Pinter M, Weinmann A.

Liver Cancer. 2019 Oct;8(5):387-402. doi: 10.1159/000492628. Epub 2018 Oct 4.

PMID:
31768347
2.

Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy.

Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stättermayer AF, Pinter M, Hernández-Gea V, Fritzer-Szekeres M, Steindl-Munda P, Trauner M, Peck-Radosavljevic M, García-Pagán JC, Ferenci P, Reiberger T.

Hepatology. 2019 Jul 31. doi: 10.1002/hep.30885. [Epub ahead of print]

PMID:
31365764
3.

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.

Iavarone M, Invernizzi F, Czauderna C, Sanduzzi-Zamparelli M, Bhoori S, Amaddeo G, Manini MA, López MF, Anders M, Pinter M, Rodríguez MJB, Cristóbal MR, Soteras GA, Piñero F, Villadsen GE, Weinmann A, Crespo G, Mazzaferro V, Regnault H, Giorgio M, González-Diéguez ML, Donato MF, Varela M, Wörns MA, Bruix J, Lampertico P, Reig M.

Am J Transplant. 2019 Nov;19(11):3176-3184. doi: 10.1111/ajt.15551. Epub 2019 Sep 3.

PMID:
31365177
4.

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma.

Scheiner B, Ulbrich G, Mandorfer M, Reiberger T, Müller C, Waneck F, Trauner M, Kölblinger C, Ferlitsch A, Sieghart W, Peck-Radosavljevic M, Pinter M.

United European Gastroenterol J. 2019 Jul;7(6):850-858. doi: 10.1177/2050640619840199. Epub 2019 Mar 21.

5.

Letter: programmed cell death protein-1-targeted immunotherapy for advanced hepatocellular carcinoma-authors' reply.

Scheiner B, Pinter M.

Aliment Pharmacol Ther. 2019 Aug;50(3):341-342. doi: 10.1111/apt.15368. No abstract available.

PMID:
31313365
7.

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension.

Semmler G, Stift J, Scheiner B, Wöran K, Schwabl P, Paternostro R, Bucsics T, Stättermayer AF, Pinter M, Ferlitsch A, Trauner M, Reiberger T, Mandorfer M.

Dig Dis Sci. 2019 Dec;64(12):3642-3651. doi: 10.1007/s10620-019-05702-7. Epub 2019 Jun 17.

8.

Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma.

Scheiner B, Kirstein M, Popp S, Hucke F, Bota S, Rohr-Udilova N, Reiberger T, Müller C, Trauner M, Peck-Radosavljevic M, Vogel A, Sieghart W, Pinter M.

Liver Cancer. 2019 May;8(3):203-217. doi: 10.1159/000489833. Epub 2018 Jun 22.

9.

C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation.

Meischl T, Rasoul-Rockenschaub S, Györi G, Sieghart W, Reiberger T, Trauner M, Soliman T, Berlakovich G, Pinter M.

PLoS One. 2019 May 29;14(5):e0216677. doi: 10.1371/journal.pone.0216677. eCollection 2019.

10.

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension.

Semmler G, Simbrunner B, Scheiner B, Schwabl P, Paternostro R, Bucsics T, Stättermayer AF, Bauer D, Pinter M, Ferenci P, Trauner M, Mandorfer M, Reiberger T.

J Gastroenterol Hepatol. 2019 May 6. doi: 10.1111/jgh.14700. [Epub ahead of print]

PMID:
31062417
11.

The long-term effects of an implantable drop foot stimulator on gait in hemiparetic patients.

Sturma A, Schuhfried O, Hasenoehrl T, Ambrozy C, Salminger S, Hruby LA, Mayer JA, Götz-Neumann K, Crevenna R, Pinter MM, Aszmann OC.

PLoS One. 2019 Apr 17;14(4):e0214991. doi: 10.1371/journal.pone.0214991. eCollection 2019.

12.

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs JB, Waneck F, Waidmann O, Reiberger T, Müller C, Sieghart W, Trauner M, Weinmann A, Wege H, Trojan J, Peck-Radosavljevic M, Vogel A, Pinter M.

Aliment Pharmacol Ther. 2019 May;49(10):1323-1333. doi: 10.1111/apt.15245. Epub 2019 Apr 12.

13.

Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information.

Stift J, Semmler G, Walzel C, Mandorfer M, Schwarzer R, Schwabl P, Paternostro R, Scheiner B, Wöran K, Pinter M, Stättermayer AF, Trauner M, Peck-Radosavljevic M, Ferlitsch A, Reiberger T.

Dig Liver Dis. 2019 Aug;51(8):1144-1151. doi: 10.1016/j.dld.2019.01.020. Epub 2019 Feb 12.

PMID:
30862438
14.

Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.

Schulte L, Scheiner B, Voigtländer T, Koch S, Schweitzer N, Marhenke S, Ivanyi P, Manns MP, Rodt T, Hinrichs JB, Weinmann A, Pinter M, Vogel A, Kirstein MM.

Liver Int. 2019 Apr;39(4):714-726. doi: 10.1111/liv.14048. Epub 2019 Feb 7.

PMID:
30663219
15.

Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?

Pinter M, Sieghart W.

Memo. 2018;11(3):185-192. doi: 10.1007/s12254-018-0431-z. Epub 2018 Aug 24. Review.

16.

Review article: systemic treatment of hepatocellular carcinoma.

Pinter M, Peck-Radosavljevic M.

Aliment Pharmacol Ther. 2018 Sep;48(6):598-609. doi: 10.1111/apt.14913. Epub 2018 Jul 23. Review.

17.

Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.

Rohr-Udilova N, Klinglmüller F, Schulte-Hermann R, Stift J, Herac M, Salzmann M, Finotello F, Timelthaler G, Oberhuber G, Pinter M, Reiberger T, Jensen-Jarolim E, Eferl R, Trauner M.

Sci Rep. 2018 Apr 18;8(1):6220. doi: 10.1038/s41598-018-24437-5.

18.

Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events.

Pinter M, Kwanten WJ, Jain RK.

Clin Cancer Res. 2018 Aug 15;24(16):3803-3812. doi: 10.1158/1078-0432.CCR-18-0236. Epub 2018 Apr 2. Review.

19.

Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, Huang Y, Rahbari NN, Roberge S, Wang D, Gomes-Santos IL, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Tolaney SM, Krop IE, Duda DG, Boucher Y, Fukumura D, Jain RK.

Sci Transl Med. 2018 Mar 14;10(432). pii: eaag0945. doi: 10.1126/scitranslmed.aag0945.

20.

Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma.

Rohr-Udilova N, Bauer E, Timelthaler G, Eferl R, Stolze K, Pinter M, Seif M, Hayden H, Reiberger T, Schulte-Hermann R, Peck-Radosavljevic M, Stoiber D, Trauner M.

Oncotarget. 2018 Jan 22;9(11):10054-10068. doi: 10.18632/oncotarget.24300. eCollection 2018 Feb 9.

21.

Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.

Pinter M, Weinmann A, Wörns MA, Hucke F, Bota S, Marquardt JU, Duda DG, Jain RK, Galle PR, Trauner M, Peck-Radosavljevic M, Sieghart W.

United European Gastroenterol J. 2017 Nov;5(7):987-996. doi: 10.1177/2050640617695698. Epub 2017 Feb 26.

22.

Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.

Pinter M, Jain RK.

Sci Transl Med. 2017 Oct 4;9(410). pii: eaan5616. doi: 10.1126/scitranslmed.aan5616. Review.

23.

Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib.

Rohr-Udilova N, Klinglmüller F, Seif M, Hayden H, Bilban M, Pinter M, Stolze K, Sieghart W, Peck-Radosavljevic M, Trauner M.

Oncotarget. 2017 Jul 6;8(34):57109-57120. doi: 10.18632/oncotarget.19055. eCollection 2017 Aug 22.

24.

Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer.

Jung K, Heishi T, Incio J, Huang Y, Beech EY, Pinter M, Ho WW, Kawaguchi K, Rahbari NN, Chung E, Kim JK, Clark JW, Willett CG, Yun SH, Luster AD, Padera TP, Jain RK, Fukumura D.

Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):10455-10460. doi: 10.1073/pnas.1710754114. Epub 2017 Sep 12.

25.

The impact of thyroid hormones on patients with hepatocellular carcinoma.

Pinter M, Haupt L, Hucke F, Bota S, Bucsics T, Trauner M, Peck-Radosavljevic M, Sieghart W.

PLoS One. 2017 Aug 3;12(8):e0181878. doi: 10.1371/journal.pone.0181878. eCollection 2017.

26.

Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma.

Liu H, Naxerova K, Pinter M, Incio J, Lee H, Shigeta K, Ho WW, Crain JA, Jacobson A, Michelakos T, Dias-Santos D, Zanconato A, Hong TS, Clark JW, Murphy JE, Ryan DP, Deshpande V, Lillemoe KD, Fernandez-Del Castillo C, Downes M, Evans RM, Michaelson J, Ferrone CR, Boucher Y, Jain RK.

Clin Cancer Res. 2017 Oct 1;23(19):5959-5969. doi: 10.1158/1078-0432.CCR-17-0256. Epub 2017 Jun 9.

27.

The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab.

Li S, Peck-Radosavljevic M, Ubl P, Wadsak W, Mitterhauser M, Rainer E, Pinter M, Wang H, Nanoff C, Kaczirek K, Haug A, Hacker M.

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1732-1741. doi: 10.1007/s00259-017-3724-2. Epub 2017 May 29.

28.

Synergy effects of combined multichannel EMG-triggered electrical stimulation and mirror therapy in subacute stroke patients with severe or very severe arm/hand paresis.

Schick T, Schlake HP, Kallusky J, Hohlfeld G, Steinmetz M, Tripp F, Krakow K, Pinter M, Dohle C.

Restor Neurol Neurosci. 2017;35(3):319-332. doi: 10.3233/RNN-160710.

PMID:
28506003
29.

Cancer and liver cirrhosis: implications on prognosis and management.

Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W.

ESMO Open. 2016 Mar 17;1(2):e000042. eCollection 2016. Review.

30.

Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy.

Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, Ng MR, Nia HT, Grahovac J, Kao S, Babykutty S, Huang Y, Jung K, Rahbari NN, Han X, Chauhan VP, Martin JD, Kahn J, Huang P, Desphande V, Michaelson J, Michelakos TP, Ferrone CR, Soares R, Boucher Y, Fukumura D, Jain RK.

Cancer Discov. 2016 Aug;6(8):852-69. doi: 10.1158/2159-8290.CD-15-1177. Epub 2016 May 31.

31.

Airway Progenitor Clone Formation Is Enhanced by Y-27632-Dependent Changes in the Transcriptome.

Reynolds SD, Rios C, Wesolowska-Andersen A, Zhuang Y, Pinter M, Happoldt C, Hill CL, Lallier SW, Cosgrove GP, Solomon GM, Nichols DP, Seibold MA.

Am J Respir Cell Mol Biol. 2016 Sep;55(3):323-36. doi: 10.1165/rcmb.2015-0274MA.

32.

Synaptic Deficits at Neuromuscular Junctions in Two Mouse Models of Charcot-Marie-Tooth Type 2d.

Spaulding EL, Sleigh JN, Morelli KH, Pinter MJ, Burgess RW, Seburn KL.

J Neurosci. 2016 Mar 16;36(11):3254-67. doi: 10.1523/JNEUROSCI.1762-15.2016.

33.

Abnormal response of distal Schwann cells to denervation in a mouse model of motor neuron disease.

Carrasco DI, Bahr BA, Seburn KL, Pinter MJ.

Exp Neurol. 2016 Apr;278:116-26. doi: 10.1016/j.expneurol.2016.02.002. Epub 2016 Feb 4.

34.

Reversible Recruitment of a Homeostatic Reserve Pool of Synaptic Vesicles Underlies Rapid Homeostatic Plasticity of Quantal Content.

Wang X, Pinter MJ, Rich MM.

J Neurosci. 2016 Jan 20;36(3):828-36. doi: 10.1523/JNEUROSCI.3786-15.2016.

35.

Altered terminal Schwann cell morphology precedes denervation in SOD1 mice.

Carrasco DI, Seburn KL, Pinter MJ.

Exp Neurol. 2016 Jan;275 Pt 1:172-81. doi: 10.1016/j.expneurol.2015.09.014. Epub 2015 Sep 26.

36.

A Short CEP135 Splice Isoform Controls Centriole Duplication.

Dahl KD, Sankaran DG, Bayless BA, Pinter ME, Galati DF, Heasley LR, Giddings TH Jr, Pearson CG.

Curr Biol. 2015 Oct 5;25(19):2591-6. doi: 10.1016/j.cub.2015.08.039. Epub 2015 Sep 24.

37.

Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.

Pinter M, Ulbrich G, Sieghart W, Kölblinger C, Reiberger T, Li S, Ferlitsch A, Müller C, Lammer J, Peck-Radosavljevic M.

Radiology. 2015 Dec;277(3):903-12. doi: 10.1148/radiol.2015142140. Epub 2015 Jul 1.

PMID:
26131911
38.

Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement.

Albanese A, Abbruzzese G, Dressler D, Duzynski W, Khatkova S, Marti MJ, Mir P, Montecucco C, Moro E, Pinter M, Relja M, Roze E, Skogseid IM, Timerbaeva S, Tzoulis C.

J Neurol. 2015 Oct;262(10):2201-13. doi: 10.1007/s00415-015-7703-x. Epub 2015 Apr 1. Review.

39.

Sodium channel slow inactivation as a therapeutic target for myotonia congenita.

Novak KR, Norman J, Mitchell JR, Pinter MJ, Rich MM.

Ann Neurol. 2015 Feb;77(2):320-32. doi: 10.1002/ana.24331. Epub 2015 Jan 9.

40.

Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2(loxP/loxP) Villin-Cre mice.

Kortüm B, Campregher C, Lang M, Khare V, Pinter M, Evstatiev R, Schmid G, Mittlböck M, Scharl T, Kucherlapati MH, Edelmann W, Gasche C.

Gut. 2015 Dec;64(12):1905-12. doi: 10.1136/gutjnl-2014-307663. Epub 2014 Nov 26.

41.

Epidemiological trends of hepatocellular carcinoma in Austria.

Pinter M, Hucke F, Zielonke N, Trauner M, Sieghart W, Peck-Radosavljevic M.

Dig Dis. 2014;32(6):664-9. doi: 10.1159/000367983. Epub 2014 Oct 29.

PMID:
25376282
42.

How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma.

Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M, Sieghart W.

J Hepatol. 2014 Dec;61(6):1287-96. doi: 10.1016/j.jhep.2014.07.002. Epub 2014 Jul 10.

PMID:
25016222
43.

Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma.

Pinter M, Sieghart W, Schmid M, Dauser B, Prager G, Dienes HP, Trauner M, Peck-Radosavljevic M.

United European Gastroenterol J. 2013 Aug;1(4):265-75. doi: 10.1177/2050640613496605.

44.

Towards using NMR to screen for spoiled tomatoes stored in 1,000 L, aseptically sealed, metal-lined totes.

Pinter MD, Harter T, McCarthy MJ, Augustine MP.

Sensors (Basel). 2014 Mar 3;14(3):4167-76. doi: 10.3390/s140304167.

45.

Expression pattern and biochemical properties of zebrafish N-acetylglutamate synthase.

Caldovic L, Haskins N, Mumo A, Majumdar H, Pinter M, Tuchman M, Krufka A.

PLoS One. 2014 Jan 22;9(1):e85597. doi: 10.1371/journal.pone.0085597. eCollection 2014.

46.

Prevention of poststroke cognitive decline: ASPIS--a multicenter, randomized, observer-blind, parallel group clinical trial to evaluate multiple lifestyle interventions--study design and baseline characteristics.

Brainin M, Matz K, Nemec M, Teuschl Y, Dachenhausen A, Asenbaum-Nan S, Bancher C, Kepplinger B, Oberndorfer S, Pinter M, Schnider P, Tuomilehto J; ASPIS Study Group.

Int J Stroke. 2015 Jun;10(4):627-35. doi: 10.1111/ijs.12188. Epub 2013 Nov 10.

PMID:
24206541
47.

Incidence and mortality trends for biliary tract cancers in Austria.

Pinter M, Hucke F, Zielonke N, Waldhör T, Trauner M, Peck-Radosavljevic M, Sieghart W.

Liver Int. 2014 Aug;34(7):1102-8. doi: 10.1111/liv.12325. Epub 2013 Oct 2.

PMID:
24119058
48.

The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE.

Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M.

J Hepatol. 2014 Jan;60(1):118-26. doi: 10.1016/j.jhep.2013.08.022. Epub 2013 Sep 3.

PMID:
24012941
49.

Role of repetitive transcranial magnetic stimulation in stroke rehabilitation.

Pinter MM, Brainin M.

Front Neurol Neurosci. 2013;32:112-21. doi: 10.1159/000346433. Epub 2013 Jul 8. Review.

50.

The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma.

Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Trauner M, Peck-Radosavljevic M.

Hepatology. 2013 Jun;57(6):2261-73. doi: 10.1002/hep.26256. Epub 2013 May 3.

PMID:
23316013

Supplemental Content

Loading ...
Support Center